Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.

Journal Article (Clinical Trial;Journal Article)

Crizotinib, a dual MET/ALK inhibitor, is now in advanced clinical development for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). We have observed several patients who developed profound but asymptomatic sinus bradycardia (HR ≤45) during the course of crizotinib treatment. Herein, we describe the clinical characteristics of three separate patients enrolled in the A8081001 trial (NCT00585195) who developed asymptomatic profound sinus bradycardia with their accompanying electrocardiogram tracings.

Full Text

Duke Authors

Cited Authors

  • Ou, S-HI; Azada, M; Dy, J; Stiber, JA

Published Date

  • December 2011

Published In

Volume / Issue

  • 6 / 12

Start / End Page

  • 2135 - 2137

PubMed ID

  • 22088989

Electronic International Standard Serial Number (EISSN)

  • 1556-1380

Digital Object Identifier (DOI)

  • 10.1097/JTO.0b013e3182307e06


  • eng

Conference Location

  • United States